PASIMAT: Automatic Measure of PASI
NCT02808559 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2016-06-21
Summary
To quantify the severity of psoriasis in a consistent and clinically meaningful way is important in order to decide the therapeutic orientation to take for the patient. PASI (Psoriasis Area and Severity Index) scoring is recognised as gold standard for psoriasis assessment. The bodystudio ATBM (Automatic Total Body Mapping) is a high-tech system performing standardized photos from head to feet and from all angles, which allows to map the entire skin covering all the human body in a few minutes.The primary objective of this study would be to evaluate the ability of the bodystudio ATBM to calculate the PASI score of patients with psoriasis human body in a few minutes
Conditions
Interventions
- DEVICE
-
Bodystudio ATBM (Automatic Total Body Mapping)
The mapping of the entire body is automatically done using a high-resolution apparatus (20 photographs of the patient in 8 positions (face, back, lateral left and right, specific extremities) The photographs will be done with a standardized procedure established by FotoFinder. Every lesion is completely evaluated and the PASI score can be calculated.
Sponsors & Collaborators
- collaborator INDUSTRY
-
Fotofinder
collaborator UNKNOWN -
Centre Hospitalier Universitaire de Nice
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-11-30
- Primary Completion
- 2015-05-31
- Completion
- 2015-05-31
More Related Trials
-
Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis
NCT05111210 ·Status: RECRUITING
-
Therapeutic Drug Monitoring of Risankizumab in Psoriasis Patients (BIOLOPTIM-RIS)
NCT05685940 ·Status: RECRUITING ·Phase: PHASE4
-
Immune Signature of Palmoplantar Pustulosis
NCT01780857 ·Status: COMPLETED
-
Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis
NCT00192452 ·Status: COMPLETED ·Phase: PHASE2
-
Etanercept Plus UVB-311nm Phototherapy in Psoriasis
NCT00550030 ·Status: COMPLETED ·Phase: NA
-
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
NCT00941031 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis
NCT00329303 ·Status: COMPLETED ·Phase: PHASE2
-
Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis
NCT02412644 ·Status: COMPLETED ·Phase: PHASE4
-
Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
NCT04841187 ·Status: COMPLETED
-
The Disease Severity In Patients With Psoriasis
NCT05943405 ·Status: COMPLETED
-
DC-STAMP & TRAF3: Regulators of Osteoclastogenesis and Biomarkers in PsA
NCT02413749 ·Status: COMPLETED
-
Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study
NCT05185258 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis
NCT02595970 ·Status: COMPLETED ·Phase: PHASE3
-
Psorcast Mobile Study
NCT05621369 ·Status: RECRUITING
-
Personal Precise Treatment on Psoriasis and Psoriatic Arthritis
NCT04915105 ·Status: UNKNOWN ·Phase: NA
-
A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)
NCT02394561 ·Status: COMPLETED ·Phase: PHASE3
-
A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
NCT01071252 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis
NCT01510951 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Study of Ointment for the Treatment of Plaque-type Psoriasis
NCT01258088 ·Status: COMPLETED ·Phase: PHASE1
-
A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis
NCT00885196 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496 ·Status: RECRUITING ·Phase: PHASE3
-
An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO)
NCT05959070 ·Status: COMPLETED
-
Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis
NCT01617018 ·Status: COMPLETED
-
This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is
NCT03635099 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of LZM012
NCT06110676 ·Status: RECRUITING ·Phase: PHASE3